NASDAQ:MDCO - Medicines Stock Price, Price Target & More

$29.45 -0.63 (-2.09 %)
(As of 04/22/2018 04:00 PM ET)
Previous Close$29.45
Today's Range$29.39 - $30.13
52-Week Range$24.45 - $53.16
Volume529,811 shs
Average Volume846,582 shs
Market Capitalization$2.16 billion
P/E Ratio-3.51
Dividend YieldN/A
Beta0.65

About Medicines (NASDAQ:MDCO)

Medicines logoThe Medicines Company, a biopharmaceutical company, provides medicines to treat acute and intensive care patients. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for patients undergoing percutaneous coronary intervention in the United States. It primarily focuses on developing Inclisiran, a lipid-lowering drug to reduce LDL-cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease or cardiovascular risk-equivalents. The company has collaboration agreements with Alnylam Pharmaceuticals, Inc.; SciClone Pharmaceuticals; and Symbio Pharmaceuticals Limited. The Medicines Company was founded in 1996 and is based in Parsippany, New Jersey.

Receive MDCO News and Ratings via Email

Sign-up to receive the latest news and ratings for MDCO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:MDCO
CUSIP58468810
Phone973-290-6000

Debt

Debt-to-Equity Ratio26.06%
Current Ratio3.21%
Quick Ratio3.18%

Price-To-Earnings

Trailing P/E Ratio-3.51
Forward P/E Ratio-10.87
P/E GrowthN/A

Sales & Book Value

Annual Sales$44.79 million
Price / Sales48.18
Cash FlowN/A
Price / CashN/A
Book Value$0.34 per share
Price / Book86.62

Profitability

EPS (Most Recent Fiscal Year)($8.40)
Net Income$-708,370,000.00
Net Margins-1,035.27%
Return on Equity-316.40%
Return on Assets-59.67%

Miscellaneous

Employees170
Outstanding Shares73,280,000

How to Become a New Pot Stock Millionaire

Medicines (NASDAQ:MDCO) Frequently Asked Questions

What is Medicines' stock symbol?

Medicines trades on the NASDAQ under the ticker symbol "MDCO."

How were Medicines' earnings last quarter?

Medicines (NASDAQ:MDCO) issued its earnings results on Wednesday, February, 21st. The company reported ($2.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.48) by $0.71. The firm earned $8.60 million during the quarter, compared to the consensus estimate of $20.71 million. Medicines had a negative return on equity of 316.40% and a negative net margin of 1,035.27%. Medicines's revenue for the quarter was down 50.6% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.19) earnings per share. View Medicines' Earnings History.

When is Medicines' next earnings date?

Medicines is scheduled to release their next quarterly earnings announcement on Wednesday, April, 25th 2018. View Earnings Estimates for Medicines.

What price target have analysts set for MDCO?

7 brokerages have issued 12 month price objectives for Medicines' stock. Their predictions range from $40.00 to $85.00. On average, they expect Medicines' share price to reach $52.00 in the next twelve months. View Analyst Ratings for Medicines.

What are Wall Street analysts saying about Medicines stock?

Here are some recent quotes from research analysts about Medicines stock:
  • 1. According to Zacks Investment Research, "The Medicines Co.’s Angiomax sales eroding due to presence of generics. the company’s ability to successfully develop and bring in new products to the market is highly important for growth. Any regulatory setback would weigh heavily on the stock. The company’s shares have underperformed the industry in a year’s time. However, pipeline boasts a potential blockbuster candidate, inclisiran. Moreover, the company implemented a workforce lay-off last year for better alignment of its cost and structure. We are also encouraged by The Medicines Co.’s regular divestiture of non-core products. This would help optimize its capital structure and enhance its liquidity position. Estimates have been stable lately ahead of the company’s Q1 earnings release. The company has negative record of earnings surprises in recent quarters." (4/17/2018)
  • 2. Chardan Capital analysts commented, "We found particularly notable: (1) MDCO completing recruitment in just 11 weeks for its 1500-patient ORION-11 pivotal phase III trial of siRNA- based PSCK9 synthesis inhibitor inclisiran (partnered with Alnylam, Buy) and may thus have its first top-line pivotal results in 3Q19, (2) the confirmation commercial scale manufacturing for inclisiran has been achieved, and (3) new inclisiran efficacy data in HoFH to us suggesting efficacy beyond mAb PCSK9 inhibitors. With inclisiran to us having clear momentum towards 2H19E pivotal data and what we expect will be $4.7 billion in 2030E peak sales, we make MDCO a Chardan Top Pick for 2018." (1/24/2018)

Who are some of Medicines' key competitors?

Who are Medicines' key executives?

Medicines' management team includes the folowing people:
  • Dr. Fredric N. Eshelman, Exec. Chairman (Age 69)
  • Dr. Clive A. Meanwell, CEO & Director (Age 60)
  • Mr. Stephen M. Rodin J.D., Exec. VP, Gen. Counsel & Sec. (Age 42)
  • Mr. Christopher T. Cox, Chief Corp. Devel. Officer and Exec. VP (Age 53)
  • Mr. William B. O'Connor, Special Advisor to the Chief Exec. Officer (Age 59)

Has Medicines been receiving favorable news coverage?

Press coverage about MDCO stock has trended somewhat positive this week, according to Accern Sentiment Analysis. The research group scores the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Medicines earned a coverage optimism score of 0.16 on Accern's scale. They also gave media headlines about the company an impact score of 47.19 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

How do I buy shares of Medicines?

Shares of MDCO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Medicines' stock price today?

One share of MDCO stock can currently be purchased for approximately $29.45.

How big of a company is Medicines?

Medicines has a market capitalization of $2.16 billion and generates $44.79 million in revenue each year. The company earns $-708,370,000.00 in net income (profit) each year or ($8.40) on an earnings per share basis. Medicines employs 170 workers across the globe.

How can I contact Medicines?

Medicines' mailing address is 8 SYLVAN WAY, PARSIPPANY NJ, 07054. The company can be reached via phone at 973-290-6000 or via email at [email protected]


MarketBeat Community Rating for Medicines (MDCO)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  373 (Vote Outperform)
Underperform Votes:  238 (Vote Underperform)
Total Votes:  611
MarketBeat's community ratings are surveys of what our community members think about Medicines and other stocks. Vote "Outperform" if you believe MDCO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDCO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Medicines (NASDAQ:MDCO) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
7 Wall Street analysts have issued ratings and price targets for Medicines in the last 12 months. Their average twelve-month price target is $52.00, suggesting that the stock has a possible upside of 76.57%. The high price target for MDCO is $85.00 and the low price target for MDCO is $40.00. There are currently 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.002.80
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $52.00$52.00$54.75$54.40
Price Target Upside: 76.57% upside58.34% upside120.50% upside64.20% upside

Medicines (NASDAQ:MDCO) Consensus Price Target History

Price Target History for Medicines (NASDAQ:MDCO)

Medicines (NASDAQ:MDCO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/22/2018OppenheimerReiterated RatingBuyLowView Rating Details
2/23/2018Jefferies GroupReiterated RatingBuy$47.00LowView Rating Details
1/24/2018Chardan CapitalReiterated RatingBuy$85.00HighView Rating Details
1/24/2018JPMorgan ChaseReiterated RatingOverweight -> Overweight$45.00HighView Rating Details
1/22/2018CitigroupUpgradeNeutral -> Buy$40.00HighView Rating Details
10/23/2017GuggenheimInitiated CoverageBuy$45.00N/AView Rating Details
8/10/2017CowenReiterated RatingBuy$61.00 -> $54.00HighView Rating Details
5/23/2017CIBCSet Price Target$50.00MediumView Rating Details
3/20/2017HC WainwrightReiterated RatingBuy$60.00HighView Rating Details
3/1/2017Royal Bank of CanadaReiterated RatingBuyN/AView Rating Details
11/8/2016Leerink SwannReiterated RatingOutperform$53.00 -> $50.00N/AView Rating Details
7/12/2016Bank of AmericaReiterated RatingBuyN/AView Rating Details
(Data available from 4/22/2016 forward)

Earnings

Medicines (NASDAQ:MDCO) Earnings History and Estimates Chart

Earnings by Quarter for Medicines (NASDAQ:MDCO)

Medicines (NASDAQ:MDCO) Earnings Estimates

2018 EPS Consensus Estimate: ($2.85)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183($1.02)($0.64)($0.85)
Q2 20183($0.94)($0.63)($0.83)
Q3 20183($0.78)($0.44)($0.59)
Q4 20183($0.72)($0.45)($0.59)

Medicines (NASDAQ MDCO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/25/2018($0.82)N/AView Earnings Details
2/21/2018Q4 2017($1.48)($2.19)$20.71 million$8.60 millionViewListenView Earnings Details
10/25/2017Q3 2017($1.37)($0.42)$26.06 million$16.87 millionViewN/AView Earnings Details
8/9/2017Q2 2017($1.29)($5.52)$29.64 million$18.74 millionViewListenView Earnings Details
4/26/2017Q1 2017($1.13)($1.44)$37.76 million$24.20 millionViewN/AView Earnings Details
2/28/2017Q416($1.43)($1.29)$26.91 million$25.20 millionViewListenView Earnings Details
10/26/2016Q316($1.38)($0.64)$37.26 million$37.60 millionViewListenView Earnings Details
7/27/2016Q216($1.16)($0.62)$41.93 million$54.70 millionViewListenView Earnings Details
5/9/2016Q116($0.89)($1.03)$48.96 million$50.30 millionViewListenView Earnings Details
2/17/2016Q415($1.54)($0.88)$64.11 million$67.20 millionViewN/AView Earnings Details
11/3/2015Q315($0.88)($0.90)$68.58 million$72.70 millionViewListenView Earnings Details
7/29/2015Q215($0.20)($0.74)$122.58 million$90.50 millionViewListenView Earnings Details
5/5/2015Q115($0.68)($0.02)$138.78 million$126.50 millionViewListenView Earnings Details
2/18/2015Q414($0.84)$0.11$188.55 million$191.00 millionViewListenView Earnings Details
10/22/2014Q314($0.10)$0.10$188.30 million$172.40 millionViewListenView Earnings Details
7/23/2014Q214($0.07)$0.22$183.75 million$183.80 millionViewListenView Earnings Details
4/23/2014Q114($0.13)$0.22$175.60 million$177.20 millionViewListenView Earnings Details
2/19/2014Q413$0.11$0.26$182.60 million$185.00 millionViewListenView Earnings Details
10/23/2013Q313$0.24$0.47$173.86 million$173.45 millionViewListenView Earnings Details
7/24/2013Q2 2013$0.33$0.50$168.70 million$172.00 millionViewListenView Earnings Details
4/24/2013Q1 2013($0.26)$0.31$152.63 million$155.80 millionViewListenView Earnings Details
2/20/2013Q4 2012$0.28$0.38$146.09 million$159.50 millionViewListenView Earnings Details
10/24/2012$0.39$0.40ViewN/AView Earnings Details
7/25/2012$0.22$0.46ViewN/AView Earnings Details
4/25/2012$0.14$0.27ViewN/AView Earnings Details
2/22/2012$0.24$0.52ViewN/AView Earnings Details
10/26/2011$0.20$0.17ViewN/AView Earnings Details
7/27/2011$0.31$0.21ViewN/AView Earnings Details
4/27/2011$0.40$0.45ViewN/AView Earnings Details
2/16/2011$0.24$0.30ViewN/AView Earnings Details
10/27/2010Q3 2010$0.24$0.40ViewN/AView Earnings Details
7/28/2010Q2 2010$0.23$0.29ViewN/AView Earnings Details
4/28/2010Q1 2010$0.13$0.19ViewN/AView Earnings Details
2/15/2010Q4 2009($1.40)ViewN/AView Earnings Details
10/28/2009Q3 2009($0.05)($0.06)ViewN/AView Earnings Details
7/29/2009Q2 2009$0.05$0.07ViewN/AView Earnings Details
4/29/2009Q1 2009($0.03)($0.04)ViewN/AView Earnings Details
2/18/2009Q4 2008$0.03($0.08)ViewN/AView Earnings Details
7/23/2008Q2 2008$0.07$0.08ViewN/AView Earnings Details
4/23/2008Q1 2008$0.06$0.09ViewN/AView Earnings Details
2/13/2008Q4 2007$0.02$0.03ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Medicines (NASDAQ:MDCO) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Medicines (NASDAQ MDCO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 8.22%
Insider Trading History for Medicines (NASDAQ:MDCO)
Institutional Ownership by Quarter for Medicines (NASDAQ:MDCO)

Medicines (NASDAQ MDCO) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/16/2018Armin M. KesslerDirectorSell20,000$28.71$574,200.00View SEC Filing  
3/21/2018William CrouseDirectorSell7,500$32.26$241,950.0060,633View SEC Filing  
12/15/2017Clive MeanwellCEOSell136,250$27.24$3,711,450.00587,652View SEC Filing  
12/8/2017Fredric N EshelmanInsiderBuy200,000$26.56$5,312,000.001,028,383View SEC Filing  
11/29/2017Alexander J DennerDirectorBuy170,000$30.03$5,105,100.006,663View SEC Filing  
2/7/2017William Bernard O'connorCFOSell25,833$46.20$1,193,484.6030,935View SEC Filing  
12/8/2016Christopher T CoxEVPBuy105,500$33.20$3,502,600.0033,670View SEC Filing  
12/8/2016Fredric N EshelmanDirectorBuy621,720$33.77$20,995,484.40641,106View SEC Filing  
9/21/2016Clive MeanwellCEOSell8,623$40.00$344,920.00347,791View SEC Filing  
9/1/2016Clive MeanwellCEOSell1,377$40.00$55,080.00339,168View SEC Filing  
8/24/2016Clive MeanwellCEOSell20,000$40.00$800,000.00358,790View SEC Filing  
7/11/2016Hiroaki ShigetaDirectorSell3,849$38.50$148,186.5023,547View SEC Filing  
6/10/2016Christopher T CoxEVPBuy45,985$37.90$1,742,831.5033,670View SEC Filing  
6/7/2016Christopher T CoxEVPBuy53,340$37.55$2,002,917.0020,800View SEC Filing  
5/24/2016Melvin K SpigelmanDirectorSell15,000$37.00$555,000.0053,970View SEC Filing  
5/16/2016Clive MeanwellCEOSell10,000$35.00$350,000.00348,790View SEC Filing  
5/16/2016William CrouseDirectorSell15,000$35.15$527,250.0053,970View SEC Filing  
5/13/2016Elizabeth H S WyattDirectorSell15,000$34.07$511,050.0049,817View SEC Filing  
5/12/2016Fredric N EshelmanDirectorBuy300,000$33.68$10,104,000.00300,000View SEC Filing  
3/7/2016Armin M KesslerDirectorSell8,100$34.82$282,042.00144,930View SEC Filing  
11/13/2015Robert G. SavageDirectorSell5,000$39.34$196,700.0027,720View SEC Filing  
9/3/2015Glenn SblendorioCFOSell25,000$42.00$1,050,000.0099,805View SEC Filing  
8/31/2015Clive MeanwellCEOSell49,998$39.36$1,967,921.28324,905View SEC Filing  
8/31/2015Glenn SblendorioCFOSell114,495$39.75$4,551,176.2599,805View SEC Filing  
8/31/2015Melvin K. SpigelmanDirectorSell20,000$40.50$810,000.0038,970View SEC Filing  
8/31/2015William Bernard O'connorSVPSell35,451$40.00$1,418,040.0024,732View SEC Filing  
7/1/2015Clive MeanwellCEOSell16,667$28.39$473,176.13View SEC Filing  
6/25/2015Glenn SblendorioCFOSell3,305$32.00$105,760.00View SEC Filing  
6/8/2015Hiroaki ShigetaDirectorSell7,500$28.99$217,425.00View SEC Filing  
5/20/2015Robert G SavageDirectorSell15,000$26.78$401,700.00View SEC Filing  
4/16/2015William Bernard O'connorSVPSell1,281$30.00$38,430.00View SEC Filing  
4/1/2015Clive MeanwellCEOSell16,667$27.58$459,675.86View SEC Filing  
3/30/2015Elizabeth H S WyattDirectorSell20,000$28.08$561,600.00View SEC Filing  
3/23/2015Clive MeanwellCEOSell16,667$30.62$510,343.54View SEC Filing  
3/23/2015Glenn SblendorioCFOSell34,773$30.78$1,070,312.94View SEC Filing  
3/2/2015William Bernard O'connorSVPSell2,988$28.78$85,994.64View SEC Filing  
3/3/2014William Bernard O'connorSVPSell2,968$30.31$89,960.0827,870View SEC Filing  
1/21/2014Paul Michael AntinoriVPSell37,883$38.02$1,440,311.6631,029View SEC Filing  
1/15/2014William Bernard O'connorSVPSell4,427$39.15$173,317.0525,058View SEC Filing  
1/10/2014William Bernard O'connorSVPSell72,384$40.00$2,895,360.0025,058View SEC Filing  
1/7/2014Clive MeanwellCEOSell27,929$38.13$1,064,932.77297,773View SEC Filing  
1/3/2014Clive MeanwellCEOSell57,516$38.16$2,194,810.56297,773View SEC Filing  
12/9/2013William CrouseDirectorSell12,500$38.00$475,000.0029,849View SEC Filing  
12/5/2013Glenn SblendorioCFOSell8,516$38.50$327,866.00118,405View SEC Filing  
12/2/2013Clive MeanwellCEOSell10,000$36.58$365,800.00307,773View SEC Filing  
11/26/2013Clive MeanwellCEOSell135,000$36.70$4,954,500.00317,773View SEC Filing  
10/23/2013William Bernard O'connorSVPSell6,354$35.00$222,390.00View SEC Filing  
9/13/2013Paul Michael AntinoriVPSell73,500$34.50$2,535,750.0051,906View SEC Filing  
9/3/2013Clive MeanwellCEOSell7,500$31.85$238,875.00View SEC Filing  
8/1/2013Clive MeanwellCEOSell7,500$31.26$234,450.00View SEC Filing  
7/8/2013Paul Michael AntinoriVPSell36,000$33.00$1,188,000.00View SEC Filing  
7/1/2013Clive MeanwellCEOSell7,500$31.25$234,375.00View SEC Filing  
6/11/2013Paul Michael AntinoriVPSell109,973$33.29$3,661,001.17View SEC Filing  
5/29/2013Armin M KesslerDirectorSell8,750$33.05$289,187.50View SEC Filing  
5/10/2013Glenn SblendorioCFOSell2,709$37.00$100,233.00View SEC Filing  
5/9/2013Paul Michael AntinoriVPSell35,000$34.90$1,221,500.00View SEC Filing  
5/9/2013William Bernard O'connorSVPSell29,654$35.00$1,037,890.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Medicines (NASDAQ MDCO) News Headlines

Source:
DateHeadline
Transparency Life Science Founder Tomasz Sablinski Tops "Champions of Change" in The Medicine Makers 2018 ...Transparency Life Science Founder Tomasz Sablinski Tops "Champions of Change" in The Medicine Maker's 2018 ...
www.prnewswire.com - April 20 at 5:01 PM
The Medicines Patent Pool Governance Board Appoints Charles Gore as New MPP Executive DirectorThe Medicines Patent Pool Governance Board Appoints Charles Gore as New MPP Executive Director
www.prnewswire.com - April 20 at 5:01 PM
$8.79 Million in Sales Expected for The Medicines Company (MDCO) This Quarter$8.79 Million in Sales Expected for The Medicines Company (MDCO) This Quarter
www.americanbankingnews.com - April 20 at 2:36 AM
The Medicines Company to Announce First-Quarter 2018 Financial Results on April 25The Medicines Company to Announce First-Quarter 2018 Financial Results on April 25
finance.yahoo.com - April 19 at 9:08 AM
The Medicines Company (MDCO) Director Armin M. Kessler Sells 20,000 SharesThe Medicines Company (MDCO) Director Armin M. Kessler Sells 20,000 Shares
www.americanbankingnews.com - April 18 at 7:29 PM
-$0.71 Earnings Per Share Expected for The Medicines Company (MDCO) This Quarter-$0.71 Earnings Per Share Expected for The Medicines Company (MDCO) This Quarter
www.americanbankingnews.com - April 18 at 3:08 PM
New PhRMA report shows over 500 medicines in development for neurological disordersNew PhRMA report shows over 500 medicines in development for neurological disorders
www.prnewswire.com - April 18 at 9:08 AM
The Medicines (MDCO) Lowered to Sell at Zacks Investment ResearchThe Medicines (MDCO) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - April 17 at 12:47 PM
The Medicines (MDCO) Set to Announce Quarterly Earnings on TuesdayThe Medicines (MDCO) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - April 17 at 3:46 AM
The Medicines (MDCO) Lifted to Buy at Zacks Investment ResearchThe Medicines (MDCO) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - April 12 at 7:25 PM
The Medicines Company (MDCO) Receives Consensus Recommendation of "Buy" from AnalystsThe Medicines Company (MDCO) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 12 at 1:41 PM
Biotech activist Alex Denner’s next target: Ironwood PharmaBiotech activist Alex Denner’s next target: Ironwood Pharma
finance.yahoo.com - April 9 at 5:04 PM
The Medicines (MDCO) Lowered to "Strong Sell" at Zacks Investment ResearchThe Medicines (MDCO) Lowered to "Strong Sell" at Zacks Investment Research
www.americanbankingnews.com - April 7 at 4:58 PM
BidaskClub Downgrades The Medicines (MDCO) to SellBidaskClub Downgrades The Medicines (MDCO) to Sell
www.americanbankingnews.com - April 5 at 9:52 AM
Elsalys Biotech : LEUKOTAC takes next step in paediatric acute steroid-resistant GvHDElsalys Biotech : LEUKOTAC takes next step in paediatric acute steroid-resistant GvHD
feeds.benzinga.com - April 5 at 4:12 AM
 Analysts Anticipate The Medicines Company (MDCO) Will Post Quarterly Sales of $8.79 Million Analysts Anticipate The Medicines Company (MDCO) Will Post Quarterly Sales of $8.79 Million
www.americanbankingnews.com - April 3 at 3:21 AM
EMA to Review Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell CarcinomaEMA to Review Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma
www.prnewswire.com - April 3 at 1:33 AM
EMA to Review DUPIXENT® (dupilumab) as Potential Treatment for Inadequately Controlled Moderate-to-Severe AsthmaEMA to Review DUPIXENT® (dupilumab) as Potential Treatment for Inadequately Controlled Moderate-to-Severe Asthma
www.prnewswire.com - April 3 at 1:33 AM
 Analysts Anticipate The Medicines Company (MDCO) to Post -$0.77 EPS Analysts Anticipate The Medicines Company (MDCO) to Post -$0.77 EPS
www.americanbankingnews.com - April 1 at 3:20 PM
The Medicines (MDCO) Raised to "Hold" at BidaskClubThe Medicines (MDCO) Raised to "Hold" at BidaskClub
www.americanbankingnews.com - March 30 at 11:06 AM
New Large-Scale Trial Results Show Stiolto® Respimat® Prevents COPD Exacerbations Better Than Spiriva ...New Large-Scale Trial Results Show Stiolto® Respimat® Prevents COPD Exacerbations Better Than Spiriva ...
www.prnewswire.com - March 29 at 9:06 AM
Shire Reports Regulatory Milestones for Investigational Hereditary Angioedema (HAE) Treatment LanadelumabShire Reports Regulatory Milestones for Investigational Hereditary Angioedema (HAE) Treatment Lanadelumab
feeds.benzinga.com - March 29 at 3:13 AM
The Medicines (MDCO) PT Set at $50.00 by OppenheimerThe Medicines (MDCO) PT Set at $50.00 by Oppenheimer
www.americanbankingnews.com - March 28 at 3:48 PM
Homology Medicines opens at $23, up 44% from IPO priceHomology Medicines opens at $23, up 44% from IPO price
seekingalpha.com - March 28 at 10:34 AM
The Medicines Company announces CFO transitionThe Medicines Company announces CFO transition
seekingalpha.com - March 28 at 6:54 AM
The Medicines (MDCO) Lifted to Buy at CitigroupThe Medicines (MDCO) Lifted to Buy at Citigroup
www.americanbankingnews.com - March 27 at 12:40 AM
[$$] Business school: book prize, engineering talent, cost of an MBA[$$] Business school: book prize, engineering talent, cost of an MBA
finance.yahoo.com - March 26 at 9:46 AM
Shire and NanoMedSyn Enter Into Research Agreement for Potential Lysosomal Storage Disorder TreatmentShire and NanoMedSyn Enter Into Research Agreement for Potential Lysosomal Storage Disorder Treatment
feeds.benzinga.com - March 26 at 3:45 AM
[$$] How to manage a Brexit-enforced move[$$] How to manage a Brexit-enforced move
finance.yahoo.com - March 25 at 5:13 PM
The Medicines (MDCO) Downgraded by BidaskClubThe Medicines (MDCO) Downgraded by BidaskClub
www.americanbankingnews.com - March 24 at 6:13 PM
William Crouse Sells 7,500 Shares of The Medicines Company (MDCO) StockWilliam Crouse Sells 7,500 Shares of The Medicines Company (MDCO) Stock
www.americanbankingnews.com - March 23 at 7:34 PM
The Medicines Company (MDCO) Up 4.8% Since Earnings Report: Can It Continue?The Medicines Company (MDCO) Up 4.8% Since Earnings Report: Can It Continue?
finance.yahoo.com - March 23 at 6:13 PM
The Medicines (MDCO) Earns Buy Rating from OppenheimerThe Medicines (MDCO) Earns Buy Rating from Oppenheimer
www.americanbankingnews.com - March 22 at 4:05 PM
The Medicines Company CEO, Dr. Clive Meanwell, On The Impact Of ODYSSEY OUTCOMES For Heart PatientsThe Medicines Company CEO, Dr. Clive Meanwell, On The Impact Of ODYSSEY OUTCOMES For Heart Patients
finance.yahoo.com - March 20 at 8:42 AM
The Medicines Company (MDCO) Given Average Recommendation of "Buy" by BrokeragesThe Medicines Company (MDCO) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - March 18 at 1:50 PM
The Medicines (MDCO) Stock Rating Upgraded by BidaskClubThe Medicines (MDCO) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - March 17 at 5:36 PM
Zacks: Analysts Expect The Medicines Company (MDCO) Will Announce Quarterly Sales of $8.79 MillionZacks: Analysts Expect The Medicines Company (MDCO) Will Announce Quarterly Sales of $8.79 Million
www.americanbankingnews.com - March 17 at 4:58 AM
The Medicines Company (MDCO) Expected to Announce Earnings of -$0.77 Per ShareThe Medicines Company (MDCO) Expected to Announce Earnings of -$0.77 Per Share
www.americanbankingnews.com - March 15 at 11:22 AM
Investors Purchase High Volume of Put Options on The Medicines (MDCO)Investors Purchase High Volume of Put Options on The Medicines (MDCO)
www.americanbankingnews.com - March 15 at 6:35 AM
[$$] Brexit and the ‘NHS dividend’[$$] Brexit and the ‘NHS dividend’
finance.yahoo.com - March 14 at 11:55 AM
The Medicines Company (MDCO) Expected to Earn Q1 2018 Earnings of ($0.64) Per ShareThe Medicines Company (MDCO) Expected to Earn Q1 2018 Earnings of ($0.64) Per Share
www.americanbankingnews.com - March 14 at 7:20 AM
The Medicines Company up 6% premarket on Praluent price cut - Seeking AlphaThe Medicines Company up 6% premarket on Praluent price cut - Seeking Alpha
seekingalpha.com - March 13 at 5:21 PM
Odyssey Outcomes: Making Regenerons Stock Great Again?Odyssey Outcomes: Making Regeneron's Stock Great Again?
seekingalpha.com - March 13 at 10:26 AM
The Medicines (MDCO) Given a $50.00 Price Target by Oppenheimer AnalystsThe Medicines (MDCO) Given a $50.00 Price Target by Oppenheimer Analysts
www.americanbankingnews.com - March 12 at 1:35 PM
Alnylam Pharmaceuticals (ALNY) Up 1.6% Since Earnings Report: Can It Continue?Alnylam Pharmaceuticals (ALNY) Up 1.6% Since Earnings Report: Can It Continue?
finance.yahoo.com - March 12 at 6:13 AM
Menarini Group gibt Zulassungsantrag für Delafloxacin bekanntMenarini Group gibt Zulassungsantrag für Delafloxacin bekannt
www.prnewswire.com - March 10 at 10:54 AM
The Medicines Company to Participate in the Cowen 38th Annual Health Care ConferenceThe Medicines Company to Participate in the Cowen 38th Annual Health Care Conference
finance.yahoo.com - March 8 at 5:05 PM
The Medicines Company to Participate in the Cowen 38th Annual ... - Business Wire (press release)The Medicines Company to Participate in the Cowen 38th Annual ... - Business Wire (press release)
www.businesswire.com - March 8 at 10:02 AM
[$$] EU rejects UK’s plans for post-Brexit trade relationship[$$] EU rejects UK’s plans for post-Brexit trade relationship
finance.yahoo.com - March 7 at 9:28 AM
The Medicines Company (MDCO) Shares Bought by University of Notre Dame DU LacThe Medicines Company (MDCO) Shares Bought by University of Notre Dame DU Lac
www.americanbankingnews.com - March 6 at 3:40 PM

SEC Filings

Medicines (NASDAQ:MDCO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Medicines (NASDAQ:MDCO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Medicines (NASDAQ MDCO) Stock Chart for Sunday, April, 22, 2018

Loading chart…

This page was last updated on 4/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.